Novavax Q2 2024: Sanofi Deal Boosts Revenueby Mark Eisenberg 09.08.2024Novavax reports $415M in Q2 revenue with Sanofi's help, eyeing new vaccine launches and cost reductions.
Biotech Stocks: Potential Soar of 120% and 295%by Mark Eisenberg 25.04.2024Iovance Biotherapeutics has the potential to become a multiproduct company, and even if its stock doesn't soar quickly, it's still ...
Teladoc Health Vs. Novavax: Stock Picks and Avoidanceby Mark Eisenberg 09.04.2024Teladoc Health's revenue grew by 8% to $2.6 billion in 2023, with a gross margin of 70.8%. On the other ...